Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

603 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Design, Synthesis, and Biological Evaluation of New 1-(Aryl-1 H-pyrrolyl)(phenyl)methyl-1 H-imidazole Derivatives as Antiprotozoal Agents.
Saccoliti F, Madia VN, Tudino V, De Leo A, Pescatori L, Messore A, De Vita D, Scipione L, Brun R, Kaiser M, Mäser P, Calvet CM, Jennings GK, Podust LM, Pepe G, Cirilli R, Faggi C, Di Marco A, Battista MR, Summa V, Costi R, Di Santo R. Saccoliti F, et al. Among authors: di marco a, di santo r. J Med Chem. 2019 Feb 14;62(3):1330-1347. doi: 10.1021/acs.jmedchem.8b01464. Epub 2019 Jan 23. J Med Chem. 2019. PMID: 30615444
Discovery of 2-(1H-imidazo-2-yl)piperazines as a new class of potent and non-cytotoxic inhibitors of Trypanosoma brucei growth in vitro.
Ferrigno F, Biancofiore I, Malancona S, Ponzi S, Paonessa G, Graziani R, Bresciani A, Gennari N, Di Marco A, Kaiser M, Summa V, Harper S, Ontoria JM. Ferrigno F, et al. Among authors: di marco a. Bioorg Med Chem Lett. 2018 Dec 15;28(23-24):3689-3692. doi: 10.1016/j.bmcl.2018.10.028. Epub 2018 Oct 22. Bioorg Med Chem Lett. 2018. PMID: 30482621
Design and synthesis of bicyclic pyrimidinones as potent and orally bioavailable HIV-1 integrase inhibitors.
Muraglia E, Kinzel O, Gardelli C, Crescenzi B, Donghi M, Ferrara M, Nizi E, Orvieto F, Pescatore G, Laufer R, Gonzalez-Paz O, Di Marco A, Fiore F, Monteagudo E, Fonsi M, Felock PJ, Rowley M, Summa V. Muraglia E, et al. Among authors: di marco a. J Med Chem. 2008 Feb 28;51(4):861-74. doi: 10.1021/jm701164t. Epub 2008 Jan 25. J Med Chem. 2008. PMID: 18217703
Improved Selective Class I HDAC and Novel Selective HDAC3 Inhibitors: Beyond Hydroxamic Acids and Benzamides.
Bresciani A, Ontoria JM, Biancofiore I, Cellucci A, Ciammaichella A, Di Marco A, Ferrigno F, Francone A, Malancona S, Monteagudo E, Nizi E, Pace P, Ponzi S, Rossetti I, Veneziano M, Summa V, Harper S. Bresciani A, et al. Among authors: di marco a. ACS Med Chem Lett. 2018 Nov 27;10(4):481-486. doi: 10.1021/acsmedchemlett.8b00517. eCollection 2019 Apr 11. ACS Med Chem Lett. 2018. PMID: 30996783 Free PMC article.
5,6-Dihydroxypyrimidine Scaffold to Target HIV-1 Nucleocapsid Protein.
Malancona S, Mori M, Fezzardi P, Santoriello M, Basta A, Nibbio M, Kovalenko L, Speziale R, Battista MR, Cellucci A, Gennari N, Monteagudo E, Di Marco A, Giannini A, Sharma R, Pires M, Real E, Zazzi M, Dasso Lang MC, De Forni D, Saladini F, Mely Y, Summa V, Harper S, Botta M. Malancona S, et al. Among authors: di marco a. ACS Med Chem Lett. 2020 Mar 19;11(5):766-772. doi: 10.1021/acsmedchemlett.9b00608. eCollection 2020 May 14. ACS Med Chem Lett. 2020. PMID: 32435383 Free PMC article.
Discovery of a Selective Series of Inhibitors of Plasmodium falciparum HDACs.
Ontoria JM, Paonessa G, Ponzi S, Ferrigno F, Nizi E, Biancofiore I, Malancona S, Graziani R, Roberts D, Willis P, Bresciani A, Gennari N, Cecchetti O, Monteagudo E, Orsale MV, Veneziano M, Di Marco A, Cellucci A, Laufer R, Altamura S, Summa V, Harper S. Ontoria JM, et al. Among authors: di marco a. ACS Med Chem Lett. 2016 Mar 5;7(5):454-9. doi: 10.1021/acsmedchemlett.5b00468. eCollection 2016 May 12. ACS Med Chem Lett. 2016. PMID: 27190592 Free PMC article.
Studies of the metabolic stability in cells of 5-(trifluoroacetyl)thiophene-2-carboxamides and identification of more stable class II histone deacetylase (HDAC) inhibitors.
Scarpelli R, Di Marco A, Ferrigno F, Laufer R, Marcucci I, Muraglia E, Ontoria JM, Rowley M, Serafini S, Steinkühler C, Jones P. Scarpelli R, et al. Among authors: di marco a. Bioorg Med Chem Lett. 2008 Dec 1;18(23):6078-82. doi: 10.1016/j.bmcl.2008.10.041. Epub 2008 Oct 12. Bioorg Med Chem Lett. 2008. PMID: 18952417
Identification of novel, selective, and stable inhibitors of class II histone deacetylases. Validation studies of the inhibition of the enzymatic activity of HDAC4 by small molecules as a novel approach for cancer therapy.
Ontoria JM, Altamura S, Di Marco A, Ferrigno F, Laufer R, Muraglia E, Palumbi MC, Rowley M, Scarpelli R, Schultz-Fademrecht C, Serafini S, Steinkühler C, Jones P. Ontoria JM, et al. Among authors: di marco a. J Med Chem. 2009 Nov 12;52(21):6782-9. doi: 10.1021/jm900555u. J Med Chem. 2009. PMID: 19888759
Application of an in Vitro Blood-Brain Barrier Model in the Selection of Experimental Drug Candidates for the Treatment of Huntington's Disease.
Di Marco A, Gonzalez Paz O, Fini I, Vignone D, Cellucci A, Battista MR, Auciello G, Orsatti L, Zini M, Monteagudo E, Khetarpal V, Rose M, Dominguez C, Herbst T, Toledo-Sherman L, Summa V, Muñoz-Sanjuán I. Di Marco A, et al. Mol Pharm. 2019 May 6;16(5):2069-2082. doi: 10.1021/acs.molpharmaceut.9b00042. Epub 2019 Apr 4. Mol Pharm. 2019. PMID: 30916978
603 results